Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant SKB-264 + tislelizumab for resectable NSCLC
ChiCTR2600117859Phase 2Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan and tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Pathological complete remission rate (pCR). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecantislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600117859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117859.